Mutation Pattern Similarity broadens potential of existing Therapies

Scientists at Queen’s University Belfast and the University of Birmingham have revealed that tumours normally found in blood cancers with mutations in the SF3B1 gene, are capable of responding to some existing PARP inhibitors, a type of drug used to treat cancers which carry similar mutations in the BRCA1 and BRCA2 genes. Click to read more...

Related Keywords

United States ,Belfast ,United Kingdom ,American ,Katrina Lappin ,Cancer Research ,American Association For Cancer Research ,United Kingdom Medical Research Council ,Scientists At Queen University Belfast ,Cancer Research United Kingdom ,University Of Birmingham ,Hospital Children Charity ,University Belfast ,Kienan Savage ,Patrickg Johnson Centre ,Professor Grant Stewart ,Blood Cancer United Kingdom ,Great Ormond Street Hospital Children ,American Association ,Cancer ,Utation ,Cancers ,Mutations ,Carp ,Flood ,Author ,Treatment ,Arca ,Patients ,